Myriad Genetics Inc (NASDAQ:MYGN)
| 27.37 Delayed Data As of May 14 |  +1.69 / +6.58%Today’s Change | 10.54 Today|||52-Week Range 33.97 | +38.41% Year-to-Date |
Latest MYGN News | Press Releases
| Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues May 05 / Zacks.com - Paid Partner Content | Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates May 03 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 25.68 |
| Today’s open | 25.89 |
| Day’s range | 25.74 - 27.39 |
| Volume | 12,551 |
| Average volume (3 months) | 743,981 |
| Market cap | $2.1B |
Data as of 3:59pm ET, 05/14/2021
Growth & Valuation
| Earnings growth (last year) | -4,389.30% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +6.00% |
| Revenue growth (last year) | -24.97% |
| P/E ratio | NM |
| Price/Sales | 1.32 |
| Price/Book | 2.19 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LNTHLantheus Holdings In... | +0.35 | +1.69% |
| VCYTVeracyte Inc | +1.41 | +4.01% |
| CLDXCelldex Therapeutics... | +2.02 | +8.08% |
| TRILTrillium Therapeutic... | +0.20 | +2.31% |
Data as of 4:00pm ET, 05/14/2021
Financials
| Next reporting date | September 1, 2021 |
| EPS forecast (this quarter) | -$0.11 |
| Annual revenue (last year) | $638.6M |
| Annual profit (last year) | -$199.5M |
| Net profit margin | -31.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Salt Lake City, Utah |
Forecasts
